# OnCo record paper-libretto-531-nejm-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-libretto-531-nejm-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-libretto-531-nejm-2023" ;
  schema:name "LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer"@en ;
  schema:description "The selective RET inhibitor selpercatinib cut the risk of progression by more than 70 percent compared with the older multikinase drugs cabozantinib and vandetanib in RET-mutant medullary thyroid cancer, with fewer side effects."@en ;
  schema:url <https://onco.cc/key-papers/paper-libretto-531-nejm-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2309719>, <https://pubmed.ncbi.nlm.nih.gov/37870969/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2309719> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Hadoux J, Elisei R, Brose MS, et al." ;
  onco:cancers <https://onco.cc/cancers/medullary-thyroid-cancer/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/> ;
  onco:trials <https://onco.cc/trials/libretto-531/> ;
  onco:journals <https://onco.cc/journals/nejm/> .